Literature DB >> 34459212

Heart Failure and a Preserved Ejection Fraction: A Side-by-Side Examination of the PARAGON-HF and EMPEROR-Preserved Trials.

Milton Packer1,2, Faiez Zannad3, Stefan D Anker4.   

Abstract

Entities:  

Keywords:  heart failure

Mesh：

Year:  2021        PMID： 34459212     DOI： 10.1161/CIRCULATIONAHA.121.056657

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  7 in total

1.  Immunometabolic Mechanisms of Heart Failure with Preserved Ejection Fraction.

Authors:  Gabriele G Schiattarella; Pilar Alcaide; Gianluigi Condorelli; Thomas G Gillette; Stephane Heymans; Elizabeth A V Jones; Marinos Kallikourdis; Andrew Lichtman; Federica Marelli-Berg; Sanjiv Shah; Edward B Thorp; Joseph A Hill
Journal:  Nat Cardiovasc Res       Date:  2022-03-14

Review 2.  Fibrotic Signaling in Cardiac Fibroblasts and Vascular Smooth Muscle Cells: The Dual Roles of Fibrosis in HFpEF and CAD.

Authors:  Julian C Bachmann; Simon J Baumgart; Anna K Uryga; Markus H Bosteen; Giulia Borghetti; Michael Nyberg; Kate M Herum
Journal:  Cells       Date:  2022-05-17       Impact factor: 7.666

3.  Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial.

Authors:  Milton Packer; Javed Butler; Faiez Zannad; Gerasimos Filippatos; Joao Pedro Ferreira; Stuart J Pocock; Peter Carson; Inder Anand; Wolfram Doehner; Markus Haass; Michel Komajda; Alan Miller; Steen Pehrson; John R Teerlink; Sven Schnaidt; Cordula Zeller; Janet M Schnee; Stefan D Anker
Journal:  Circulation       Date:  2021-08-29       Impact factor: 29.690

Review 4.  Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy.

Authors:  Mauro Gori; Emilia D'Elia; Edoardo Sciatti; Michele Senni
Journal:  Card Fail Rev       Date:  2022-07-08

5.  Characteristics, prognosis, and treatment response in HFpEF patients with high vs. normal ejection fraction.

Authors:  Jun Gu; Jia-Han Ke; Yue Wang; Chang-Qian Wang; Jun-Feng Zhang
Journal:  Front Cardiovasc Med       Date:  2022-09-09

6.  Effects of high-absorption curcumin for the prevention of hypertensive heart disease: a double-blind, placebo-controlled, randomized clinical study.

Authors:  Masafumi Funamoto; Yoichi Sunagawa; Yasufumi Katanasaka; Toru Kato; Junichi Funada; Yoichi Ajiro; Maki Komiyama; Masaharu Akao; Akihiro Yasoda; Hajime Yamakage; Noriko Satoh-Asahara; Hiromichi Wada; Yasumasa Ikeda; Tatsuya Morimoto; Koji Hasegawa
Journal:  Eur Heart J Open       Date:  2022-09-10

7.  Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction.

Authors:  Javed Butler; Milton Packer; Gerasimos Filippatos; Joao Pedro Ferreira; Cordula Zeller; Janet Schnee; Martina Brueckmann; Stuart J Pocock; Faiez Zannad; Stefan D Anker
Journal:  Eur Heart J       Date:  2022-02-03       Impact factor: 29.983
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.